Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
INZY - Inozyme Pharma, Inc.
Market Cap 209.17M P/E - EPS this Y -9.50% Ern Qtrly Grth -
Income -71.17M Forward P/E -2.73 EPS next Y -6.70% 50D Avg Chg -19.00%
Sales - PEG -0.22 EPS past 5Y - 200D Avg Chg 28.00%
Dividend N/A Price/Book 2.01 EPS next 5Y 13.10% 52W High Chg -35.00%
Recommedations 1.60 Quick Ratio 12.87 Shares Outstanding 61.77M 52W Low Chg 379.00%
Insider Own 0.66% ROA -27.81% Shares Float 34.13M Beta 1.37
Inst Own 92.98% ROE -54.98% Shares Shorted/Prior 3.15M/2.38M Price 4.75
Gross Margin - Profit Margin - Avg. Volume 617,506 Target Price 20.33
Oper. Margin - Earnings Date May 7 Volume 604,578 Change -5.38%
Healthcare | Biotechnology | United States
About Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Inozyme Pharma, Inc. News
04/08/24 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
04/05/24 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/24 Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
03/26/24 Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
03/12/24 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
02/26/24 Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
12/21/23 Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
11/09/23 Inozyme Pharma to Participate in Upcoming Investor Conferences
11/07/23 Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
10/26/23 Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
10/14/23 10 Stocks With Huge Catalysts on the Way
10/10/23 Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
10/10/23 Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
10/06/23 Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
09/26/23 Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
09/20/23 Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
09/05/23 Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/08/23 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
08/07/23 Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)
08/01/23 Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
INZY Chatroom

User Image FlynancialAnalyst Posted - 1 day ago

Don't get to $INZY bc the 🧠📈 can rotate in a $SNAP !

User Image comeuppins Posted - 5 days ago

$INZY Taking my earnings over to $AGBA good luck everyone one

User Image SocioCobb Posted - 1 week ago

$INZY 93% tute, soon to be 110%..

User Image windyhawk Posted - 1 week ago

$INZY hmmm, the current trend is so puzzling to me

User Image FlymetotheMoon1738 Posted - 1 week ago

$INZY any info on what’s going on here?

User Image torabisu Posted - 2 weeks ago

$INZY wtf?

User Image Will2ride1 Posted - 2 weeks ago

$INZY watch for the pop📈

User Image maikelm82 Posted - 2 weeks ago

$ASMB this wants 15 $MREO AND $PDSB added a bit $INZY buying again soon $XBI

User Image TeamOscar Posted - 2 weeks ago

$INZY I think why they are down is due to the amount of time tell the next mile stone in the path way.

User Image FlynancialAnalyst Posted - 2 weeks ago

It pays to not get too $INZY

User Image FlynancialAnalyst Posted - 2 weeks ago

$INZY Starter 4 me

User Image FlynancialAnalyst Posted - 2 weeks ago

$INZY (qtrly) From here it's a $1.30 down vs many more up. The quarterly volume shelf should hold. See the wkly close $XBI Institutions love this one ... #ShareStats at TrendEdge.app/asset/INZY

User Image HppyTom Posted - 2 weeks ago

$INZY What kind of bulls*it is this? There is no reason for such a huge drop. Or what am I missing?

User Image SocioCobb Posted - 2 weeks ago

@MansasAlgo Do you see ANY reason this won't recover the channel and re-establish the uptrend. $INZY has performed beautifully for a while. News today was solid. 93% tute ownership would suggest manipulation/accumulation sell the news "activity." Thoughts?

User Image MansasAlgo Posted - 2 weeks ago

$INZY first bad trade of the year, lucky my pockets are deep... loading the dips for the rest of the week

User Image flexdiggs Posted - 2 weeks ago

$INZY good data yet price tanks, makes sense

User Image torabisu Posted - 2 weeks ago

$INZY 💩

User Image canadian_trader Posted - 2 weeks ago

$INZY will open over $7 IMO.

User Image canadian_trader Posted - 2 weeks ago

$INZY % held by institutions is almost 92%

User Image canadian_trader Posted - 2 weeks ago

$INZY moving back up

User Image canadian_trader Posted - 2 weeks ago

$INZY conference call started!

User Image torabisu Posted - 2 weeks ago

$INZY weak

User Image PlsBanAgain Posted - 2 weeks ago

$INZY Positive News Released

User Image DonCorleone77 Posted - 2 weeks ago

$INZY 2 of 2 - Inozyme announces 'positive' results from Phase 1/2 trials of INZ-701 "....The high risk of ischemic stroke in pediatric patients with ABCC6 Deficiency and its devastating consequences represents a serious unmet need in this population," commented Professor Zulf Mughal, M.D., Consultant in Paediatric Bone Disorders at Al Jalila Children's Specialty Hospital, Dubai, UAE. "I am very encouraged to see that INZ-701 may improve vascular pathology and believe that this effect may translate to clinical benefits in patients of all ages."

User Image DonCorleone77 Posted - 2 weeks ago

$INZY 1 of 2 - Inozyme announces 'positive' results from Phase 1/2 trials of INZ-701 Inozyme Pharma announced positive topline safety, pharmacokinetic, pharmacodynamic and exploratory efficacy data from the company's ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency. "We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency," said Douglas Treco, Ph.D., CEO of Inozyme Pharma. "Our investigations into the natural history of this disease have identified a substantial and previously overlooked pediatric population with a high risk of stroke. We believe these patients represent a critical unmet need in this genetic disease and that changes observed in adults treated with INZ-701 will translate to clinical benefits in a future trial in children...."

User Image Stock_Titan Posted - 2 weeks ago

$INZY Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency https://www.stocktitan.net/news/INZY/inozyme-pharma-announces-positive-topline-data-from-ongoing-phase-1-ksglxj25elxv.html

User Image Glider549 Posted - 2 weeks ago

$INZY Today is a possible catalyst.

User Image Stock_Titan Posted - 3 weeks ago

$INZY Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/INZY/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-rule-425d4d4v1dtb.html

User Image SocioCobb Posted - 3 weeks ago

$INZY EAZY ENTRY 👀

User Image canadian_trader Posted - 3 weeks ago

$INZY this is why you don't use stop losses for biotech.

Analyst Ratings
Needham Buy Apr 10, 24
B of A Securities Buy Apr 9, 24
Needham Buy Apr 9, 24
HC Wainwright & Co. Buy Mar 13, 24
Needham Buy Mar 12, 24
Wedbush Outperform Jan 30, 24
Needham Buy Nov 8, 23
Needham Buy Sep 27, 23
Wedbush Outperform Sep 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pivotal bioVenture Partners Fu... Director Director Aug 01 Buy 4.8 833,333 3,999,998 1,571,741 08/03/23
Hopfner Robert Lorne Director Director Aug 01 Buy 4.8 833,333 3,999,998 1,571,741 08/03/23
Hopfner Robert Lorne Director Director May 11 Buy 6.37 447,932 2,853,327 3,661,518 05/15/23
Hopfner Robert Lorne Director Director Mar 29 Buy 4.5379 344,592 1,563,724 3,213,586 03/30/23
Hopfner Robert Lorne Director Director Mar 27 Buy 3.93 207,840 816,811 2,868,994 03/29/23
Bjarke Henric Bjorn SVP, COO SVP, COO Dec 15 Buy 1.39 21,500 29,885 105,441 12/19/22
Longitude Capital Partners III... 10% Owner 10% Owner Apr 19 Buy 3.69 1,355,000 4,999,950 4,174,379 04/21/22
Pivotal bioVenture Partners Fu... Director Director Apr 19 Buy 3.69 1,070,000 3,948,300 2,661,154 04/20/22
Bjarke Henric Bjorn SVP, COO SVP, COO Apr 19 Buy 3.69 27,100 99,999 80,626 04/20/22
Bolte Axel Chief Executive Offi.. Chief Executive Officer Apr 19 Buy 3.69 67,750 249,998 258,575 04/20/22
Hopfner Robert Lorne Director Director Apr 19 Buy 3.69 1,070,000 3,948,300 2,661,154 04/20/22
Subramanian Sanjay SVP, CFO SVP, CFO Apr 19 Buy 3.69 27,100 99,999 27,100 04/20/22